BEHRANG AMINI to Drug Administration Schedule
This is a "connection" page, showing publications BEHRANG AMINI has written about Drug Administration Schedule.
Connection Strength
0.024
-
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
Score: 0.024
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.